Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Peptide based enteral formula · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Peptide Based enteral formula | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Peptide based enteral formula | OTHER | Sole source nutrition as per HCP |
Inclusion Criteria: * Male or nonpregnant female between 1 and 13 years of age. * Subject is diagnosed with gastrointestinal dysfunction and/or feeding intolerance. * Subject requires enteral tube feeding as sole source of nutrition. Exclusion Criteria: * History of diabetes. * Requires artificia...
Peptide based enteral formula is used for gastrointestinal diseases and feeding intolerance. It is being studied in a pediatric population to evaluate its safe use and tolerance. The drug is currently in Phase 3 clinical development for these gastrointestinal conditions.
Abbott Laboratories (ticker: ABT) is developing Peptide based enteral formula. The company is conducting clinical trials to evaluate the safety and tolerance of this product in pediatric patients with gastrointestinal diseases and feeding intolerance.
Peptide based enteral formula is in Phase 3 clinical development. It is an investigational product and has not been approved by regulatory authorities. One Phase 3 trial has been completed to assess its safety and tolerance in a pediatric population.
Peptide based enteral formula has one completed clinical trial, NCT0119112, titled 'Evaluation of the Safe Use and Tolerance of a Peptide-based Formula in a Pediatric Population'. This Phase 3 study enrolled 27 participants in Canada and was not randomized or blinded.
Peptide based enteral formula is not FDA approved. It is an investigational product currently in Phase 3 clinical development. The completed trial, NCT0119112, evaluated safety and tolerance in a pediatric population with gastrointestinal diseases and feeding intolerance.